The use of umbilical cord blood (UCB) for therapies is advantageous because of its ease of access, non-invasive collection procedures, and more plasticity for multi-differentiation. UCB contains a large source... UCB contains a large source of hematopoietic stem cells (HSCs) that are capable of self-renewal, have increased sensitivity to various factors, and are able to generate erythroid and myeloid progenitor colonies.
- Mechanism
- Curator reviewed
The mononuclear cells originating from the hematopoietic stem cells in the umbilical cord blood are shown to have a higher immune tolerance in donors after transplants due to their immaturity and lack of class II HLA antigens. These cells are transplanted to treat various diseases, including hematological, oncological, cardiovascular, and even neurological-based pathologies. Currently, this type of therapy is being explored for the treatment of COVID-19 related effects.
- Code names
- Umbilical Cord Blood Hematopoietic Stem Cells
What you can answer from here — as of May 21, 2026
Which companies are running trials of Umbilical Cord Blood Hematopoietic Stem Cells, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account